MedTrace Logo

Lumeneye Rectoscope for Assessment on Tumor Response After Total Neoadjuvant Treatment in Rectal Cancer

NCT06189846 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 82

Last updated 2026-05-07

No results posted yet for this study

Summary

The objective of this prospective international cohort is to evaluate the LUMENEYE rectoscope for assessment on tumor response after total neoadjuvant treatment in rectal cancer.

Patients included in this study will be patients who initially will be good candidates for organ preservation. The participating centers are all expert centers in tumor assessment.

All patient assessments after neoadjuvant treatment for rectal adenocarcinoma will be included in each centre.

Conditions

Interventions

DEVICE

International Cohort

Assessing tumour response following neoadjuvant treatment in rectal cancer include : * Digital rectal examination * Rectal MRI * Rectoscopy ( Lumeneye device) The monitoring of tumour response intervals up to 6 months following completion of the neoadjuvant treatment at 8 weeks, at 16 weeks, at 24 weeks after the end of neoadjuvant treatment.

Sponsors & Collaborators

  • Bordeaux Colorectal Institute Academy

    lead OTHER

Principal Investigators

  • Quentin DENOST · Bordeaux Colorectal Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-04
Primary Completion
2025-10-17
Completion
2026-03-05

Countries

  • France
  • Italy
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06189846 on ClinicalTrials.gov